Cigna Covering XDx's AlloMap Test | GenomeWeb

NEW YORK (GenomeWeb News) – XDx said this week that health insurer Cigna has issued a positive coverage decision for XDx's AlloMap Molecular Expression Testing for potential heart transplant rejection.

The policy, which took effect immediately, applies to about 13.8 million lives covered by Cigna. Barry Kane, senior director of finance and reimbursement at XDx, said the firm is "particularly pleased" that Cigna is formally covering AlloMap for patients six months to five years post-heart transplant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.